1921
Volume 100, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Infections due to and are common yet elusive neglected filariases. Parasitological cure after treatment is very difficult to assess, as adult parasites are not accessible. Therefore, outside transmission areas, patients require a long follow-up period to ascertain the therapeutic outcome, which is impractical for non-sedentary populations such as migrants. We studied the change over time of microfilaremia, eosinophil counts, and antifilarial antibodies tested with a commercial ELISA test (Bordier Affinity Products, Crissier, Switzerland), in a retrospective cohort of patients with confirmed and infections, to evaluate the role of serology in clinical practice. After treatment, all 22 eligible patients diagnosed in our center between 2015 and 2017 reached amicrofilaremia, with microfilarial counts decreasing sharply within 2 months. Paralleling eosinophil counts, antibodies decreased in all patients, 36% of whom reached sero-reversion or near–sero-reversion in < 20 months. These findings suggest that positive serology is not just residual from a past infection, and may be used for diagnosis even when microfilaremia is negative or cannot be performed. Interestingly, antibodies and eosinophil counts increased following some, but not all, re-treatment courses. If the rise in these parameters reflects death of macrofilariae, caution is required in interpreting high eosinophil counts and antibody titers shortly after treatment, as these may reflect no need for further treatment. To optimize patients’ management, it is now pivotal to ascertain the interval between treatment and macrofilarial death and therefore whether re-treatments are required for complete clearance of parasites.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0693
2019-01-28
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/4/tpmd180693.html?itemId=/content/journals/10.4269/ajtmh.18-0693&mimeType=html&fmt=ahah

References

  1. Metzger WG, Mordmuller B, 2014. Loa loa-does it deserve to be neglected? Lancet Infect Dis 14: 353357.
    [Google Scholar]
  2. Simonsen PE, Onapa AW, Asio SM, 2011. Mansonella perstans filariasis in Africa. Acta Trop 120 (Suppl 1): S109S120.
    [Google Scholar]
  3. Chesnais CB, Takougang I, Paguele M, Pion SD, Boussinesq M, 2017. Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infect Dis 17: 108116.
    [Google Scholar]
  4. Antinori S et al., 2012. Imported Loa loa filariasis: three cases and a review of cases reported in non-endemic countries in the past 25 years. Int J Infect Dis 16: e649e662.
    [Google Scholar]
  5. Churchill DR, Morris C, Fakoya A, Wright SG, Davidson RN, 1996. Clinical and laboratory features of patients with loiasis (Loa loa filariasis) in the U.K. J Infect 33: 103109.
    [Google Scholar]
  6. Cobo F, Cabezas-Fernandez MT, Salas-Coronas J, Cabeza-Barrera MI, Vazquez-Villegas J, Soriano-Perez MJ, 2015. Filariasis in sub-Saharan immigrants attended in a health area of southern Spain: clinical and epidemiological findings. J Immigr Minor Health 17: 306309.
    [Google Scholar]
  7. Develoux M, Hennequin C, Le Loup G, Paris L, Magne D, Belkadi G, Pialoux G, 2017. Imported filariasis in Europe: a series of 31 cases from metropolitan France. Eur J Intern Med 37: e37e39.
    [Google Scholar]
  8. Gantois N, Rapp C, Gautret P, Ficko C, Savini H, Larreche S, Saidi R, Crevon L, Simon F, 2013. Imported loiasis in France: a retrospective analysis of 47 cases. Travel Med Infect Dis 11: 366373.
    [Google Scholar]
  9. Gobbi F, Beltrame A, Buonfrate D, Staffolani S, Degani M, Gobbo M, Angheben A, Marocco S, Bisoffi Z, 2017. Imported infections with Mansonella perstans nematodes, Italy. Emerg Infect Dis 23: 15391542.
    [Google Scholar]
  10. Gobbi F, Postiglione C, Angheben A, Marocco S, Monteiro G, Buonfrate D, Mascarello M, Gobbo M, Boussinesq M, Bisoffi Z, 2014. Imported loiasis in Italy: an analysis of 100 cases. Travel Med Infect Dis 12: 713717.
    [Google Scholar]
  11. Klion AD, Ottesen EA, Nutman TB, 1994. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 169: 604610.
    [Google Scholar]
  12. Nutman TB, Miller KD, Mulligan M, Ottesen EA, 1986. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 154: 1018.
    [Google Scholar]
  13. Saito M, Armstrong M, Boadi S, Lowe P, Chiodini PL, Doherty T, 2015. Clinical features of imported loiasis: a case series from the hospital for tropical diseases, London. Am J Trop Med Hyg 93: 607611.
    [Google Scholar]
  14. Boussinesq M, 2006. Loiasis. Ann Trop Med Parasitol 100: 715731.
    [Google Scholar]
  15. Fink DL, Kamgno J, Nutman TB, 2011. Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis 5: e1299.
    [Google Scholar]
  16. Toure FS et al., 1997. Detection of Loa loa-specific DNA in blood from occult-infected individuals. Exp Parasitol 86: 163170.
    [Google Scholar]
  17. Toure FS, Mavoungou E, Kassambara L, Williams T, Wahl G, Millet P, Egwang TG, 1998. Human occult loiasis: field evaluation of a nested polymerase chain reaction assay for the detection of occult infection. Trop Med Int Health 3: 505511.
    [Google Scholar]
  18. Pedram B, Pasquetto V, Drame PM, Ji Y, Gonzalez-Moa MJ, Baldwin RK, Nutman TB, Biamonte MA, 2017. A novel rapid test for detecting antibody responses to Loa loa infections. PLoS Negl Trop Dis 11: e0005741.
    [Google Scholar]
  19. Klion AD, Horton J, Nutman TB, 1999. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 29: 680682.
    [Google Scholar]
  20. Klion AD, Massougbodji A, Horton J, Ekoue S, Lanmasso T, Ahouissou NL, Nutman TB, 1993. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 168: 202206.
    [Google Scholar]
  21. Klion AD, Vijaykumar A, Oei T, Martin B, Nutman TB, 2003. Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection. J Infect Dis 187: 128133.
    [Google Scholar]
  22. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B, 1987. The use of mebendazole in the treatment of filariases due to Loa loa and Mansonella perstans. Ann Trop Med Parasitol 81: 275282.
    [Google Scholar]
  23. Duke BO, 1990. Effect of diethylcarbamazine on adult Loa in monkeys. Ann Trop Med Parasitol 84: 387392.
    [Google Scholar]
  24. Bregani ER, Rovellini A, Mbaidoum N, Magnini MG, 2006. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 100: 458463.
    [Google Scholar]
  25. Coulibaly YI et al., 2009. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 361: 14481458.
    [Google Scholar]
  26. Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ, 2011. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev 24: 459468.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0693
Loading
/content/journals/10.4269/ajtmh.18-0693
Loading

Data & Media loading...

  • Received : 24 Aug 2018
  • Accepted : 26 Nov 2018
  • Published online : 28 Jan 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error